Asset Details
Do you wish to reserve the book?
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial – Authors' reply
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial – Authors' reply
Do you wish to request the book?
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial – Authors' reply
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of vulnerable atherosclerotic plaques: the PREVENT trial – Authors' reply
2024
Overview
In the PREVENT trial, the majority of vulnerable plaques had a minimal luminal area of less than 4·0 mm 2 and a plaque burden greater than 70% on intracoronary imaging. 1 Although these criteria were key components of future coronary events in relevant trials, 2 it could be asserted that these variables are more indicative of atherosclerotic plaque burden (quantitative feature) rather than vulnerable plaque phenotype (qualitative feature). Given that plaque burden is an important factor for future revascularisation, whereas plaque phenotype changes over time, a further detailed analysis focusing on vulnerable plaque morphology (eg, thin-capped fibroatheromas) would be more informative to risk stratify high-risk atherosclerotic lesions, which could be associated with future ischaemic events, independent of plaque burden. Over the past several decades, extensive research has given us a wealth of knowledge about high-risk coronary vulnerable plaque.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.